Skip to main content
HairCited

Vitamin D supplementation for patients with alopecia areata: A protocol for systematic review and meta-analysis.

Baohua Zhu, Lan Zhang, Jun Wang, Guiyuan Tan
Other Medicine 2022 4 citations
PubMed DOI CC-BY PDF
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D36281137'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Type d'étude
Meta-analysis
Intervention
Vitamin D supplementation for patients with alopecia areata: A protocol for systematic review and meta-analysis. None
Comparateur
Placebo
Direction de l'effet
Neutral
Risque de biais
Unclear

Abstract

BACKGROUND: Several studies have reported an association between low Vitamin D (VD) levels and Alopecia areata (AA), and suggested VD preparations as a potential therapy. VD has immunomodulatory function closely associated with a variety of skin diseases, but there is no conclusive evidence to support VD supplementation for patients with AA. Therefore, we will conduct a meta-analysis to collect and evaluate the efficacy and safety of VD supplementation in the treatment of AA. METHODS: We will search the following databases according to the developed strategy: Cochrane Library, PubMed, Web of Science, EMBASE, Scopus, Google scholar for Randomized controlled trials related to VD supplementation for AA. The retrieval time is from the establishment of each database to July 2022. Two reviewers will independently complete the literature search and screening, risk of bias assessment and data extraction. Severity of Alopecia Tool, Alopecia Density and Extent, Lesional area and senstivity (score) will be the primary results. RevMan V.5.3 will be used for data analysis and synthesis. For dichotomous outcomes and the continuous outcomes, we will calculate risk ratio with 95% Confidence intervals and mean differences or standardized mean differences with 95% Confidence intervals respectively. The reporting bias will be investigated using funnel plots, and the asymmetry of the funnel plots will be explained using the Harbord modified test or the Egger's regression test. RESULTS: The results of the study expect to provide a high-quality, evidence-based recommendation on VD supplementation in the treatment of AA for clinicians. CONCLUSIONS: The study will provide scientific and useful evidence for better use of VD supplementation in treating AA.

Full Text

PDF
Loading PDF...

Figures

Tables

Table 1

Search strategy for The Cochrane Library
#1MeSH descriptor: [Vitamin D] explode all trees
#2MeSH descriptor: [Ergocalciferols] explode all trees
#3(“Calciferols”):ti,ab,kw OR (“D2, Vitamin”):ti,ab,kw OR (“Vitamin D2”):ti,ab,kw OR (“Ergocalciferol”):ti,ab,kw OR (“Vitamin D2”):ti,ab,kw
#4#2 OR #3
#5MeSH descriptor: [Cholecalciferol] explode all trees
#6(“(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol”):ti,ab,kw OR (“Calciol”):ti,ab,kw OR (“Vitamin D 3”):ti,ab,kw OR (“Vitamin D3”):ti,ab,kw OR (“Cholecalciferols”):ti,ab,kw
#7#5 OR #6
#8MeSH descriptor:[Calcitriol] explode all trees
#9(“Sitriol”):ti,ab,kw OR (“Rocaltrol”):ti,ab,kw OR (“1 alpha,25-Dihydroxyvitamin D3”):ti,ab,kw OR (“1,25-Dihydroxyvitamin D3”):ti,ab,kw
#10(“D3, 1 alpha,25-Dihydroxyvitamin”):ti,ab,kw OR (“1,25 Dihydroxyvitamin D3”):ti,ab,kw OR (“1 alpha,25-Dihydroxycholecalciferol”):ti,ab,kw
#11(“1 alpha,25 Dihydroxyvitamin D3”):ti,ab,kw OR (“1,25 Dihydroxycholecalciferol”):ti,ab,kw OR (“D3, 1,25-Dihydroxyvitamin”):ti,ab,kw
#12(“1,25-Dihydroxycholecalciferol”):ti,ab,kw OR (“Bocatriol”):ti,ab,kw OR (“Renatriol”):ti,ab,kw OR (“Calcitriol KyraMed”):ti,ab,kw
#13(“KyraMed, Calcitriol”):ti,ab,kw OR (“Osteotriol”):ti,ab,kw OR (“Calcijex”):ti,ab,kw OR (“Decostriol”):ti,ab,kw OR (“Tirocal”):ti,ab,kw
#14(“MC 1288”):ti,ab,kw OR (“MC1288”):ti,ab,kw OR (“MC-1288”):ti,ab,kw OR (“Calcitriol-Nefro”):ti,ab,kw OR (“Calcitriol Nefro”):ti,ab,kw
#15(“1,25-dihydroxy-20-epi-Vitamin D3”):ti,ab,kw OR (“1,25 dihydroxy 20 epi Vitamin D3”):ti,ab,kw OR (“D3, 1,25-dihydroxy-20-epi-Vitamin”):ti,ab,kw
#16(“1 alpha, 25-dihydroxy-20-epi-Vitamin D3”):ti,ab,kw OR (“1,25(OH)2-20epi-D3”):ti,ab,kw OR (“20-epi-1alpha,25-dihydroxycholecaliferol”):ti,ab,kw
#17(“Silkis”):ti,ab,kw OR (“Soltriol”):ti,ab,kw
#18#8 OR #9 OR #10 #11 OR #12 OR #13 #14 OR #15 OR #16 #17
#19(“alfacalcidol”):ti,ab,kw OR (“1α-hydroxyvitamin D”):ti,ab,kw OR (“25-hydroxyvitamin D ”):ti,ab,kw OR (“calcidiol”):ti,ab,kw
#20#1 OR #4 OR #7 #18 OR #19
#21MeSH descriptor: [Alopecia Areata] explode all trees
#22(“Alopecia Circumscripta”):ti,ab,kw
#23#21 OR #22
#24MeSH descriptor: [Randomized controlled trial] explode all trees
#25(“Randomized controlled trial”):ti,ab,kw OR (“Randomized”):ti,ab,kw OR (“controlled”):ti,ab,kw
#26#24 OR #25
#27#20 AND #23 AND #26

References

  1. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol, 2018
  2. Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichology, 2018
  3. Alopecia areata: a comprehensive review of pathogenesis and management. Clin Rev Allergy Immunol, 2018
  4. Retrospective review of diphencyprone in the treatment of alopecia areata. Clin Exp Dermatol, 2016
  5. Safety concerns when using novel medications to treat alopecia. Expert Opin Drug Saf, 2018
  6. The utilization of phototherapy in the department of dermatology, Hospital Kuala Lumpur: a 5-year audit. Med J Malaysia, 2018
  7. Association of alopecia areata with vitamin D and calcium levels: a systematic review and meta-analysis. Dermatol Ther (Heidelb), 2020
  8. Correlation of vitamin D and vitamin D receptor expression in patients with alopecia areata: a clinical paradigm. Int J Dermatol, 2018
  9. Serum vitamin D level is related to disease severity in pediatric alopecia areata. J Cosmet Dermatol, 2018
  10. Vitamin D and the skin: a review for dermatologists. Vitamina D y la piel. Una revisión para dermatólogos. Actas Dermosifiliogr, 2019
  11. Serum vitamin D level and disease severity of alopecia areata: a meta-regression analysis. J Am Acad Dermatol, 2018
  12. Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory [published online ahead of print, 2020 Aug 22]. JBMR Plus, 2020
  13. Psychiatric comorbidities in patients with alopecia areata in Taiwan: a case-control study. Br J Dermatol, 2012
  14. Vitamin D supplementation ameliorates severity of major depressive disorder. J Mol Neurosci, 2020
  15. Vitamin D regulates tyrosine hydroxylase expression: N-cadherin a possible mediator. Neuroscience, 2015
  16. Oxidative stress in alopecia areata: a systematic review and meta-analysis. Int J Dermatol, 2020
  17. Effects of vitamin D levels and supplementation on atopic dermatitis: a systematic review. Pediatr Dermatol, 2018
  18. Oral vitamin D3 supplementation for chronic plaque psoriasis: a randomized, double-blind, placebo-controlled trial. J Dermatolog Treat, 2018
  19. Vitamin D status and the effects of oral vitamin D treatment in children with vitiligo: a prospective study. Clin Nutr ESPEN, 2016
  20. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation [published correction appears in BMJ. 2016 Jul 21;354:i4086]. BMJ, 2015
  21. Alopecia areata investigational assessment guidelines--part II. National alopecia areata foundation. J Am Acad Dermatol, 2004
  22. Untitled Dietary Reference Intakes for Calcium and Vitamin D, 2011
  23. Objective outcome measures: collecting meaningful data on alopecia areata. J Am Acad Dermatol, 2018
  24. Alopecia areata progression index, a scoring system for evaluating overall hair loss activity in alopecia areata patients with pigmented hair: a development and reliability assessment. Dermatology, 2016
  25. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 2009
  26. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ, 2011
  27. Untitled Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated 2011], 2011
  28. Dealing with missing outcome data in meta-analysis. Res Synth Methods, 2020
  29. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002
  30. How to do a meta-analysis. Br J Math Stat Psychol, 2010
  31. Quantifying publication bias in meta-analysis. Biometrics, 2018

Used In Evidence Reviews

Similar Papers